6-9 September 2018 | Kaohsiung, Taiwan

20th Asia Pacific League of Associations for Rheumatology Congress

6-9 September 2018 | Kaohsiung, Taiwan

Biosimilar infliximab & rituximab: Expanding access to treatment for patients with RA/AS

Advanced Therapeutics within Everyone’s Reach- Celltrion Healthcare is a global biopharmaceutical company committed to delivering high-quality and affordable therapeutics for patients.
We believe that every patient deserves access to treatments they need. Based on this belief, Celltrion Healthcare has been steadfast in our mission to meet the needs of patients who previously had limited access to advanced therapeutics since our inception in 1999 by developing biosimilar products. As a result, our biosimilar products have been approved in over 80 countries and being prescribed in more than 60 countries.
Speakers
Prof. Ki Chul Shin, MD, PhD, Korea
Prof. Michael Tee, MD, FPCP, FPRA, Philippines
Prof. Dae Hyun Yoo, MD, PhD, Korea
Agenda
1030 – Welcome and introduction: BiosimilarProf. James Cheng-Chung Wei
1040 – Biosimilar infliximab: Key Clinical & Real world data in RA/ASProf. Ki Chul Shin
1100 – Pharmacoeconomic data of biosimilar infliximab & Experience sharingProf. Michael Tee
1115 – Biosimilar rituximab: Key clinical data in RAProf. Dae Hyun Yoo
1135 – Q&A